PDCD1 and non-small cell lung carcinoma: U.S. Food and Drug Administration (FDA) in 2015 approved Nivolumab (blocks PD-1) for the treatment of LUSC (and subsequently for all NSCLC histological types) after the first-line treatment with platinum doublet chemotherapy had failed.